Literature DB >> 20065083

A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon α.

Sebastian Kreil1, Katherine Waghorn, Thomas Ernst, Andrew Chase, Helen White, Rüdiger Hehlmann, Andreas Reiter, Andreas Hochhaus, Nicholas C P Cross.   

Abstract

Interferon alpha (IFN) induces variable responses in chronic myeloid leukemia (CML), with 8-30% of early chronic phase cases achieving a complete cytogenetic response. We hypothesized that polymorphic differences in genes encoding IFN signal transduction components might account for different patient responses. We studied 174 IFN-treated patients, of whom 79 achieved less than 35% Philadelphia-chromosome (Ph) positive metaphases (responders) and 95 failed to show any cytogenetic response (more than 95% Ph-positive metaphases; non-responders). We compared 17 single nucleotide polymorphisms (SNPs) at IFNAR1, IFNAR2, JAK1, TYK2, STAT1, STAT3 and STAT5a/b between the two groups and found a significant difference for rs6503691, a SNP tightly linked to STAT5a, STAT5b and STAT3 (minor allele frequency 0.16 for non-responders; 0.06 for responders, P=0.007). Levels of STAT3 mRNA correlated with rs6503691 genotype (P<0.001) as assessed by real time quantitative PCR and therefore we conclude that rs6503691 is associated with the STAT3 expression levels and response of CML patients to IFN.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20065083      PMCID: PMC2805737          DOI: 10.3324/haematol.2009.011510

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.

Authors:  Sante Tura; Michele Baccarani; Eliana Zuffa; Domenico Russo; Renato Fanin; Alfonso Zaccaria; Mauro Fiacchini
Journal:  N Engl J Med       Date:  1994-03-24       Impact factor: 91.245

Review 2.  Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

Authors:  F Bonifazi; A de Vivo; G Rosti; F Guilhot; J Guilhot; E Trabacchi; R Hehlmann; A Hochhaus; P C Shepherd; J L Steegmann; H C Kluin-Nelemans; J Thaler; B Simonsson; A Louwagie; J Reiffers; F X Mahon; E Montefusco; G Alimena; J Hasford; S Richards; G Saglio; N Testoni; G Martinelli; S Tura; M Baccarani
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

Review 3.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

4.  Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.

Authors:  R Hehlmann; H Heimpel; J Hasford; H J Kolb; H Pralle; D K Hossfeld; W Queisser; H Löffler; B Heinze; A Georgii
Journal:  Blood       Date:  1993-07-15       Impact factor: 22.113

5.  IFNalpha activates dormant haematopoietic stem cells in vivo.

Authors:  Marieke A G Essers; Sandra Offner; William E Blanco-Bose; Zoe Waibler; Ulrich Kalinke; Michel A Duchosal; Andreas Trumpp
Journal:  Nature       Date:  2009-02-11       Impact factor: 49.962

6.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

Authors:  E Beillard; N Pallisgaard; V H J van der Velden; W Bi; R Dee; E van der Schoot; E Delabesse; E Macintyre; E Gottardi; G Saglio; F Watzinger; T Lion; J J M van Dongen; P Hokland; J Gabert
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

7.  Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.

Authors:  R Hehlmann; U Berger; M Pfirrmann; A Hochhaus; G Metzgeroth; O Maywald; J Hasford; A Reiter; D K Hossfeld; H-J Kolb; H Löffler; H Pralle; W Queisser; M Griesshammer; C Nerl; R Kuse; A Tobler; H Eimermacher; A Tichelli; C Aul; M Wilhelm; J T Fischer; M Perker; C Scheid; M Schenk; J Weiss; C R Meier; S Kremers; L Labedzki; T Schmeiser; H-P Lohrmann; H Heimpel
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

8.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

Authors:  J E Sokal; E B Cox; M Baccarani; S Tura; G A Gomez; J E Robertson; C Y Tso; T J Braun; B D Clarkson; F Cervantes
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

9.  Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia.

Authors:  M Talpaz; K B McCredie; G M Mavligit; J U Gutterman
Journal:  Blood       Date:  1983-09       Impact factor: 22.113

10.  Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells.

Authors:  Ikuya Sakai; Kazuto Takeuchi; Hayato Yamauchi; Hirosi Narumi; Shigeru Fujita
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

View more
  12 in total

1.  Association between STAT3 polymorphisms and cancer risk: a meta-analysis.

Authors:  Ruicheng Yan; Fusheng Lin; Chao Hu; Shilun Tong
Journal:  Mol Genet Genomics       Date:  2015-06-11       Impact factor: 3.291

2.  Association between polymorphisms in the signal transducer and activator of transcription and dilated cardiomyopathy in the Chinese Han population.

Authors:  Ying Peng; Bin Zhou; Yanyun Wang; Yu Chen; Hui Li; Yaping Song; Lin Zhang; Li Rao
Journal:  Mol Cell Biochem       Date:  2011-09-23       Impact factor: 3.396

3.  Immunorelated gene polymorphisms associated with acute myeloid leukemia.

Authors:  Q Liu; M Hua; S Yan; C Zhang; R Wang; X Yang; F Han; M Hou; D Ma
Journal:  Clin Exp Immunol       Date:  2020-06-02       Impact factor: 4.330

4.  In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.

Authors:  Shicheng Yang; Luca Gattinoni; Gattinoni Luca; Fang Liu; Yun Ji; Zhiya Yu; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Immunol Immunother       Date:  2011-02-09       Impact factor: 6.968

Review 5.  STAT3: a target to enhance antitumor immune response.

Authors:  Heehyoung Lee; Sumanta Kumar Pal; Karen Reckamp; Robert A Figlin; Hua Yu
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

6.  STAT3 genetic variant, alone and in combination with STAT5b polymorphism, contributes to breast cancer risk and clinical outcomes.

Authors:  Haishan Zhao; Zhe Wang; Huizhe Wu; Qinghuan Xiao; Weifan Yao; Enhua Wang; Yong Liu; Minjie Wei
Journal:  Med Oncol       Date:  2014-12-07       Impact factor: 3.064

7.  Role of STAT3 in Transformation and Drug Resistance in CML.

Authors:  Rajesh R Nair; Joel H Tolentino; Lori A Hazlehurst
Journal:  Front Oncol       Date:  2012-04-10       Impact factor: 6.244

8.  STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients.

Authors:  David Schrama; Selma Ugurel; Antje Sucker; Cathrin Ritter; Marc Zapatka; Dirk Schadendorf; Jürgen Christian Becker
Journal:  Front Med (Lausanne)       Date:  2014-11-28

9.  Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab.

Authors:  Yunfei Hu; Ning Ding; Xuan Jin; Lixia Feng; Lingyan Ping; Yuqin Song; Jun Zhu
Journal:  Cancer Cell Int       Date:  2014-03-13       Impact factor: 5.722

10.  Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma.

Authors:  Ruth Heise; Philipp M Amann; Silke Ensslen; Yvonne Marquardt; Katharina Czaja; Sylvia Joussen; Daniel Beer; Rupert Abele; Gabriele Plewnia; Robert Tampé; Hans F Merk; Heike M Hermanns; Jens M Baron
Journal:  PLoS One       Date:  2016-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.